M&A Deal Summary |
|
|---|---|
| Date | 2021-04-07 |
| Target | Psyber |
| Sector | Life Science |
| Buyer(s) | ATAI Life Sciences AG |
| Deal Type | Add-on Acquisition |
SEARCH BY
ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical needs rooted in a lack of innovation in neuropsychiatry. ATAI Life Sciences is based in München, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Delaware M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2021 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-12 |
Recognify
Berlin, Germany Recognify is an entity developing a treatment for Cognitive Impairment Associated with Schizophrenia ("CIAS"). Recognify's lead compound, "RL-007", previously called FSV7-007, has exhibited a modulating effect on three mechanisms that are central to learning and memory: the cholinergic, NMDA, and GABA type B receptor systems. |
Buy | - |
